Targeted LNP & Formulation Studio | NEXUS RNA BioSolutions

Formulation parameters

Enter lipid-component molar fractions and lipid molecular weights. Four lipid-component fractions must total 100%.

Research target / indication

Target receptor / cell type

Targeting ligand class

Receptor internalization evidence

Normal-tissue / off-target expression

RNA cargo class

Ionizable lipid (mol%)

Ionizable lipid MW (g/mol)

Phospholipid (mol%)

Phospholipid MW (g/mol)

Cholesterol / sterol (mol%)

Sterol MW (g/mol)

PEG-lipid (mol%)

PEG-lipid MW (g/mol)

Total lipid (nmol)

RNA mass (µg)

Ionizable groups / lipid

RNA average nucleotide MW (g/mol)

Flow-rate ratio (aqueous:organic)

Total flow (µL/min)

Ligand–lipid (% total lipids)

Measured diameter (nm, optional)

Measured PDI (optional)

Measured encapsulation % (optional)

Lipid and flow calculations

Calculated values depend entirely on entered assumptions and molecular weights.

—Nominal N:P (molar groups:RNA phosphate)

—Total lipid mass

—Ligand–lipid input amount

—Aqueous inlet flow

—Organic inlet flow

—Nominal initial organic v/v

Lipid component ledger

Component	Molar fraction	nmol	mg

Review and QC warnings

Targeted delivery is not predicted from ligand percentage, charge, FRR or particle size. Surface accessibility, ligand affinity, circulation, tissue penetration, endosomal escape and biodistribution require empirical measurement. Nominal N:P is not effective protonation.

Targeted LNP qualification considerations

Use a risk-based, evidence-supported review rather than a computer-generated targeting score.

Ligand and receptor biology

Tissue specificity · receptor accessibility · on-target/off-tissue expression · binding/internalization · competition with native ligands

Physicochemical profile

DLS/PDI · particle concentration · encapsulation efficiency · RNA integrity · free ligand/free RNA · surface charge · stability

Cellular potency

Cell type, dose/viability, RNA expression, functional activity, controls and endosomal escape evidence

Safety and manufacturing

Innate immune activation · lipid/RNA impurities · batch comparability · sterility/endotoxin as appropriate · FTO

RNA construct architecture ↗Interpret immune assays ↗Plan bounded lipid mixture DOE ↗